NetworkNewsBreaks

TuesdayNov 17, 2020 12:48 pm

NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Requests Protocol Amendment to Phase 2b Study to Add Study Arm

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be submitting a protocol amendment request to the U.S. Food and Drug Administration (“FDA”) for its Phase 2b OPTION 2 trial of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The proposed amendment requests the potential to add a study arm that uses an immediate-release MS1819 capsule. If approved, AZRX will be able to compare data from the existing arm that uses enteric (delayed-release) capsules with data from the new arm. Everything else regarding the study, including trial objectives, endpoints and…

Continue Reading

TuesdayNov 17, 2020 12:43 pm

NetworkNewsBreaks – Wrap Technologies Inc. (NASDAQ: WRTC) Expands Sales Teams with Key Additions

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced four key additions to the company’s inside and outside sales teams, including directors of Western Regional Sales and Eastern Regional Sales. “We are excited to be introducing additional talent to our sales department,” said Tom Smith, president and interim CEO of Wrap Technologies. “We continue to see a strong pipeline of inbound requests for BolaWrap demonstrations, training and quotes, and many agencies who have previously seen demos or have been trained on the BolaWrap are now beginning to outfit their officers with our device. With 13 distributors across…

Continue Reading

TuesdayNov 17, 2020 12:20 pm

NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY product line. In addition, the company’s subsidiary, Soluble Biotech, moved into a new office and lab space and installed new equipment. POAI also signed its first contract with a pharmaceutical company for protein expression and solubility…

Continue Reading

TuesdayNov 17, 2020 12:17 pm

NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to stockholders from its CEO Dr. James Woody. The letter addresses the closing of the merger with KBLM Merger Corp IV, which resulted in 180 Life Sciences now operating as a stand-alone publicly traded company with its common stock listed on the Nasdaq Capital Market under the symbol “ATNF.” In the update, Dr. Woody shares a little about himself and the…

Continue Reading

TuesdayNov 17, 2020 11:39 am

NetworkNewsBreaks – Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Announces Q1 2021 Financial Results

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of distinct businesses, products and brands, on Monday announced its financial and operating results for the three months ended September 30, 2020. “In the first quarter of fiscal 2021, we made solid progress towards our goal of transforming Supreme Cannabis into a premium cannabis CPG company. We continued to execute on our strategy of accelerating revenue and controlling our costs, which led to sequential growth in consolidated net revenue of 24%. Recreational net revenue grew slightly compared to the fourth quarter of 2020, due largely to higher…

Continue Reading

TuesdayNov 17, 2020 11:25 am

NetworkNewsBreaks – Creatd Inc. (NASDAQ: CRTD) Announces Financial Numbers, Key Milestones for Third Quarter

Creatd (NASDAQ: CRTD), the parent company of Vocal, a proprietary technology platform for creators of all types, reported its financial numbers and outlined several business milestones achieved during its three-month and nine-month periods ending Sept. 30, 2020. Highlights of the report include Q3 revenues of $425,000, an increase of more than 32% compared to Q2 revenues of $323,000 and a fourfold increase over revenues of $91,000 for the same period last year. The company attributed the growth in revenues primarily to the increase of Vocal+ paid subscribers and the rising price points for Vocal for Brands' campaigns. Other highlights include the appointment of…

Continue Reading

TuesdayNov 17, 2020 11:01 am

NetworkNewsBreaks – The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Announces Fiscal Q2 Results

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, on Monday announced revenue of $10.8 million for the fiscal second quarter ended September 30, 2020. “During the fiscal second quarter, we made good progress toward our strategic goals, gained market share, launched innovating new products, added leading partners, and expanded into new growth markets, all while navigating through a challenging COVID environment. Our quarterly growth was impacted as various distributors reduced deliveries and cleared excess inventory built in the prior quarter. Delivery and inventory trends continued to improve…

Continue Reading

TuesdayNov 17, 2020 10:27 am

NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) to Host Conference Call to Discuss Q3 Finances, Business Update

Pressure BioSciences (OTCQB: PBIO) has scheduled a teleconference for today to release its third-quarter 2020 financial results and announce key business updates. PBIO is  a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics and other industries. The call, scheduled for today, Nov. 17, at 4:30 p.m. ET., will include a presentation followed by a Q&A session. Anyone in North America who is interested may attend the teleconference live by calling 877-407-8033 and using the verbal passcode PBI Third Quarter 2020 Financial Call and Business Update. Those living…

Continue Reading

TuesdayNov 17, 2020 10:17 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Files IND Application for Berubicin in Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for Berubicin in the treatment of Glioblastoma Multiforme (“GBM”). Pending the FDA's acceptance of the company's filing, CNS Pharmaceuticals plans to evaluate the efficacy of Berubicin in a Phase 2 Trial for adults with GBM who have failed first-line therapy and commence the trial within the first quarter of 2021. “Our laser focus from…

Continue Reading

MondayNov 16, 2020 2:19 pm

NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation Schedule for Upcoming Investor Conferences

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will participate in two upcoming investor conferences. According to the update, Processa will participate in one-on-one meetings at the Craig-Hallum Alpha Select Virtual Conference on Tuesday, Nov. 17, 2020, and the Benchmark Annual Discovery 1x1 Investor Virtual Conference on Wednesday, Nov. 18, 2020. Interested parties should contact their conference representative or [email protected] to schedule a one-on-one meeting with management. To view the full press release, visit https://nnw.fm/HY6hm About Processa Pharmaceuticals Inc.…

Continue Reading